Literature DB >> 16713924

Epidemiology of Parkinson's disease.

Lonneke M L de Lau1, Monique M B Breteler.   

Abstract

The causes of Parkinson's disease (PD), the second most common neurodegenerative disorder, are still largely unknown. Current thinking is that major gene mutations cause only a small proportion of all cases and that in most cases, non-genetic factors play a part, probably in interaction with susceptibility genes. Numerous epidemiological studies have been done to identify such non-genetic risk factors, but most were small and methodologically limited. Larger, well-designed prospective cohort studies have only recently reached a stage at which they have enough incident patients and person-years of follow-up to investigate possible risk factors and their interactions. In this article, we review what is known about the prevalence, incidence, risk factors, and prognosis of PD from epidemiological studies.

Entities:  

Mesh:

Year:  2006        PMID: 16713924     DOI: 10.1016/S1474-4422(06)70471-9

Source DB:  PubMed          Journal:  Lancet Neurol        ISSN: 1474-4422            Impact factor:   44.182


  1063 in total

1.  Comorbidity and chronic conditions in the National Social Life, Health and Aging Project (NSHAP), Wave 2.

Authors:  Terrie Vasilopoulos; Ashwin Kotwal; Megan J Huisingh-Scheetz; Linda J Waite; Martha K McClintock; William Dale
Journal:  J Gerontol B Psychol Sci Soc Sci       Date:  2014-11       Impact factor: 4.077

Review 2.  Recent advances in the genetics of Parkinson's disease.

Authors:  Ian Martin; Valina L Dawson; Ted M Dawson
Journal:  Annu Rev Genomics Hum Genet       Date:  2011       Impact factor: 8.929

3.  A search for SNCA 3' UTR variants identified SNP rs356165 as a determinant of disease risk and onset age in Parkinson's disease.

Authors:  Lucía F Cardo; Eliecer Coto; Lorena de Mena; René Ribacoba; Oswaldo Lorenzo-Betancor; Pau Pastor; Lluis Samaranch; Ignacio F Mata; Marta Díaz; Germán Moris; Manuel Menéndez; Ana I Corao; Victoria Alvarez
Journal:  J Mol Neurosci       Date:  2011-11-11       Impact factor: 3.444

4.  Concordance between severity of disease, prevalence of nonmotor symptoms, patient-reported quality of life and disability and use of medication in Parkinson's disease.

Authors:  Alberto Raggi; Matilde Leonardi; Venusia Covelli; Alberto Albanese; Paola Soliveri; Francesco Carella; Luigi Romito
Journal:  Neurol Sci       Date:  2011-11-10       Impact factor: 3.307

Review 5.  Microglia and astrocyte dysfunction in parkinson's disease.

Authors:  Tae-In Kam; Jared T Hinkle; Ted M Dawson; Valina L Dawson
Journal:  Neurobiol Dis       Date:  2020-07-28       Impact factor: 5.996

6.  GBA mutations increase risk for Lewy body disease with and without Alzheimer disease pathology.

Authors:  Debby Tsuang; James B Leverenz; Oscar L Lopez; Ronald L Hamilton; David A Bennett; Julie A Schneider; Aron S Buchman; Eric B Larson; Paul K Crane; Jeffrey A Kaye; Patricia Kramer; Randy Woltjer; Walter Kukull; Peter T Nelson; Gregory A Jicha; Janna H Neltner; Doug Galasko; Eliezer Masliah; John Q Trojanowski; Gerard D Schellenberg; Dora Yearout; Haley Huston; Allison Fritts-Penniman; Ignacio F Mata; Jia Y Wan; Karen L Edwards; Thomas J Montine; Cyrus P Zabetian
Journal:  Neurology       Date:  2012-10-03       Impact factor: 9.910

7.  Latency of subthalamic nucleus deep brain stimulation-evoked cortical activity as a potential biomarker for postoperative motor side effects.

Authors:  Zachary T Irwin; Mohammad Z Awad; Christopher L Gonzalez; Arie Nakhmani; J Nicole Bentley; Thomas A Moore; Kenneth G Smithson; Barton L Guthrie; Harrison C Walker
Journal:  Clin Neurophysiol       Date:  2020-03-12       Impact factor: 3.708

8.  Non-motor symptoms in a Flanders-Belgian population of 215 Parkinson's disease patients as assessed by the Non-Motor Symptoms Questionnaire.

Authors:  David Crosiers; Barbara Pickut; Jessie Theuns; Peter Paul De Deyn; Christine Van Broeckhoven; Pablo Martinez-Martin; K Ray Chaudhuri; Patrick Cras
Journal:  Am J Neurodegener Dis       Date:  2012-07-23

9.  Effect of STN DBS on vesicular monoamine transporter 2 and glucose metabolism in Parkinson's disease.

Authors:  Gwenn S Smith; Kelly A Mills; Greg M Pontone; W Stanley Anderson; Kate M Perepezko; James Brasic; Yun Zhou; Jason Brandt; Christopher R Butson; Daniel P Holt; William B Mathews; Robert F Dannals; Dean F Wong; Zoltan Mari
Journal:  Parkinsonism Relat Disord       Date:  2019-04-16       Impact factor: 4.891

10.  Corynoxine, a natural autophagy enhancer, promotes the clearance of alpha-synuclein via Akt/mTOR pathway.

Authors:  Lei-Lei Chen; Ju-Xian Song; Jia-Hong Lu; Zhen-Wei Yuan; Liang-Feng Liu; Siva Sundara Kumar Durairajan; Min Li
Journal:  J Neuroimmune Pharmacol       Date:  2014-02-13       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.